A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Doxylamine and Pyridoxine (BONJESTA)

Antihistamine class · 4 generic manufacturers · 4 ANDAs filed at FDA.

First FDA approval2013-05-15
Generic availableYes · 4 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$1.16/unit
6 NDCs benchmarked, lowest of all strengths.
Average NADAC
$2.96
Across all dosage forms in distribution.
Highest NADAC
$11.11
Wide spread — brand-strength NDCs still in market.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Doxylamine and Pyridoxine used for?

Doxylamine and Pyridoxine is a Antihistamine medication tracked in Medicare Part D.

Is there a generic for Doxylamine and Pyridoxine?

Yes. 4 ANDAs filed at FDA, 4 generic manufacturers currently shipping.

How much does my plan pay for Doxylamine and Pyridoxine?

Across 329 Part D plans, Doxylamine and Pyridoxine averages $2.96/unit (NADAC). Lowest available: $1.16/unit. Highest in distribution: $11.11/unit.

Is Doxylamine and Pyridoxine on the FDA shortage list?

Doxylamine and Pyridoxine has been discontinued by its manufacturer(s).

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (6 approvals on file) · NADAC unit costs: CMS NADAC weekly file (6 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.